Cutaneous Melanoma
What is the MyPath Melanoma test, and how does it work?
Featuring Alexander Witkowski, MD, PhD
Cutaneous Melanoma
What types of melanocytic lesions is the MyPath test best suited for?
Featuring Alexander Witkowski, MD, PhD
Cutaneous Melanoma
What is the difference between the MyPath Melanoma test and the DecisionDx-Melanoma test?
Featuring Alexander Witkowski, MD, PhD
Cutaneous Melanoma
What is the turnaround time for results from the MyPath Melanoma test, and how are results reported?
Featuring Alexander Witkowski, MD, PhD
Cutaneous Melanoma
Can I order the MyPath Melanoma test on a lesion that has been previously biopsied, or does it need to be planned in advance?
Featuring Alexander Witkowski, MD, PhD
Cutaneous Melanoma
Is the MyPath Melanoma test typically covered by insurance, and what should I tell patients about potential out-of-pocket costs?
Featuring Alexander Witkowski, MD, PhD
Cutaneous Melanoma
How do you incorporate MyPath results when there is histologic discordance or when pathology is borderline?
Featuring Alexander Witkowski, MD, PhD
Cutaneous Melanoma
What are your thoughts on a dermatologist ordering MyPath vs a dermatopathologist?
Featuring Alexander Witkowski, MD, PhD
Cutaneous Melanoma
How can molecular diagnostics like MyPath reduce overtreatment in certain patients?
Featuring Alexander Witkowski, MD, PhD
Cutaneous Melanoma
How do you typically approach long-term monitoring for patients with a history of severely atypical nevi or dysplastic nevi?
Featuring Alexander Witkowski, MD, PhD
Cutaneous Melanoma
What are the limitations of GEP testing in melanoma diagnosis?
Featuring Alexander Witkowski, MD, PhD
Cutaneous Melanoma
Are GEP tests meant to replace or supplement traditional pathology for melanoma?
Featuring Alexander Witkowski, MD, PhD
Cutaneous Melanoma
What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology?
Featuring Alexander Witkowski, MD, PhD
Atopic Dermatitis
How should dermatologists evaluate whether lebrikizumab is a better option than dupilumab for a given patient?
Featuring Pearl Kwong, MD
Atopic Dermatitis
Can lebrikizumab be considered for patients with mild atopic dermatitis, or is it primarily for moderate-to-severe cases?
Featuring Pearl Kwong, MD
Atopic Dermatitis
Is there flexibility in the dosing schedule for lebrikizumab to accommodate individual patient needs?
Featuring Pearl Kwong, MD
Atopic Dermatitis
How does lebrikizumab compare to JAK inhibitors in terms of safety and efficacy for patients with atopic dermatitis?
Featuring Pearl Kwong, MD
Atopic Dermatitis
What clinical factors should guide dermatologists in selecting lebrikizumab over dupilumab or tralokinumab?
Featuring Pearl Kwong, MD
Atopic Dermatitis
What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab? With Dr. Kwong
Featuring Pearl Kwong, MD
Atopic Dermatitis
What role does shared decision-making play in improving AD outcomes, and how can it be implemented in practice?
Featuring Pearl Kwong, MD
Atopic Dermatitis
What are some limitations of traditional scoring/scaling systems in assessing AD severity?
Featuring Pearl Kwong, MD
Atopic Dermatitis
How can dermatologists work with allergists to manage patients with atopic dermatitis and significant environmental or food allergies?
Featuring Pearl Kwong, MD
Skin Cancer
What is the i31-SLNB score, and how does it improve melanoma risk stratification?
Featuring Jason Rizzo, MD, PhD
24 of 812